These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 8231205)
1. Ro 44-9883, a new nonpeptide glycoprotein IIb/IIIa antagonist, prevents platelet loss during experimental cardiopulmonary bypass. Carteaux JP; Roux S; Kuhn H; Tschopp T; Colombo V; Hadváry P J Thorac Cardiovasc Surg; 1993 Nov; 106(5):834-41. PubMed ID: 8231205 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of FK633, an ultra-short acting glycoprotein IIb/IIIa antagonist on platelet preservation during and after cardiopulmonary bypass. Tabata S; Yamaguchi S; Nagamine H; Tomita S; Arai S; Takemura H; Watanabe G Eur J Cardiothorac Surg; 2004 Aug; 26(2):289-93. PubMed ID: 15296885 [TBL] [Abstract][Full Text] [Related]
3. Ro 44-9883, a new non-peptidic GPIIb-GPIIIa antagonist prevents platelet loss in a guinea pig model of extracorporeal circulation. Carteaux JP; Steiner B; Roux S Thromb Haemost; 1993 Nov; 70(5):817-21. PubMed ID: 8128440 [TBL] [Abstract][Full Text] [Related]
4. The effects of two synthetic glycoprotein IIb/IIIa antagonists, Ro 43-8857 and L-700,462, on platelet aggregation and bleeding in guinea-pigs and dogs: evidence that Ro 43-8857 is orally active. Cook NS; Bruttger O; Pally C; Hagenbach A Thromb Haemost; 1993 Nov; 70(5):838-47. PubMed ID: 8128443 [TBL] [Abstract][Full Text] [Related]
5. Platelet preservation with a glycoprotein IIb/IIIa inhibitor in a porcine cardiopulmonary bypass model. Kondo N; Suzuki Y; Wakayama F; Tamai Y; Ji K; Fukui K; Fukuda I Ann Thorac Surg; 2005 Jul; 80(1):251-7. PubMed ID: 15975376 [TBL] [Abstract][Full Text] [Related]
11. Preservation of platelet function and number by prostacyclin during cardiopulmonary bypass. Coppe D; Sobel M; Seamans L; Levine F; Salzman E J Thorac Cardiovasc Surg; 1981 Feb; 81(2):274-8. PubMed ID: 7005550 [TBL] [Abstract][Full Text] [Related]
12. Combined administration of nitric oxide gas and iloprost during cardiopulmonary bypass reduces platelet dysfunction: a pilot clinical study. Chung A; Wildhirt SM; Wang S; Koshal A; Radomski MW J Thorac Cardiovasc Surg; 2005 Apr; 129(4):782-90. PubMed ID: 15821644 [TBL] [Abstract][Full Text] [Related]
13. Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass. Kaminishi Y; Hiramatsu Y; Watanabe Y; Yoshimura Y; Sakakibara Y Ann Thorac Surg; 2004 Feb; 77(2):644-50. PubMed ID: 14759453 [TBL] [Abstract][Full Text] [Related]